Extracorporeal membrane oxygenation (ECMO) has been used for> 40 years to support
lung and heart failure; however, bleeding and thrombosis remain serious complications. The …

Extracorporeal membrane oxygenation (ECMO) causes both thrombosis and bleeding.
Major society guidelines recommend continuous, systemic anticoagulation to prevent …

Since the last decade extracorporeal membrane oxygenation (ECMO) therapy has been
widely accepted as the treatment of life-threatening cardiac and pulmonary failure …

Extracorporeal membrane oxygenation (ECMO) is a method of life support to maintain
cardiopulmonary function. Its use as a medical application has increased since its inception …

The hemostatic system poses a major problem in extracorporeal membrane oxygenation
(ECMO). The foreign surface in the extracorporeal circuit activates platelets and the clotting …

The use of extracorporeal membrane oxygenation (ECMO) support for cardiac and
respiratory failure has increased in recent years. Improvements in ECMO oxygenator and …

Extracorporeal membrane oxygenation (ECMO) support has a high incidence of both
bleeding and thrombotic complications. Despite clear differences in patient characteristics …

Extracorporeal lung support and therapeutic anticoagulation are dogmatically linked for
most clinicians in fear of clotting of the extracorporeal circuit. In the last decade, however, we …

Background and objectives Extracorporeal membrane oxygenation (ECMO) is a method of
life support for either isolated cardiac failure or respiratory failure, with or without cardiac …

Unfractionated heparin (UFH) is the anticoagulant of choice during extracorporeal
membrane oxygenation (ECMO) support. Despite its favorable pharmacologic properties …